Action WINT WINDTREE THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Windtree Therapeutics, Inc.

Actions

WINT

US97382D5014

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:01 03/05/2024 		Varia. 5j. Varia. 1 janv.
4,94 USD +14,09% Graphique intraday de Windtree Therapeutics, Inc. -5,54% -61,83%
16/04 Windtree Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI
10/04 Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Windtree Therapeutics : April'24 Corporate Presentation
Windtree Therapeutics Announces Reverse Stock Split
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
North American Morning Briefing : Stock Futures -2-
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
WINDTREE THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH LEE'S PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE ISTAROXIME, DUAL MECHANISM SERCA2A ACTIVATORS AND ROSTAFUROXIN FOR GREATER CHINA, ASIA PACIFIC REGION
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
Windtree Therapeutics, Inc. Enters into License, Development and Commercialization Agreement with Lee?s Pharmaceutical (HK) Ltd
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action WINT
  4. Actualités Windtree Therapeutics, Inc.
  5. Autres langues